BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. It consists of 15 amino acids and has demonstrated significant cytoprotective and healing properties in numerous preclinical studies. BPC-157 is being investigated for its remarkable ability to accelerate healing across the gastrointestinal tract and multiple organ systems.
In gastrointestinal applications, BPC-157 has shown efficacy across a wide spectrum of conditions. It promotes healing of esophageal, stomach, duodenal, and intestinal ulcers, including those that fail to respond to conventional therapy. It modulates sphincter function by increasing lower esophageal sphincter pressure while decreasing pyloric sphincter pressure, making it relevant for GERD management. BPC-157 also demonstrates the ability to heal fistulas including gastrocutaneous, duodenocutaneous, and colocutaneous fistulas, and to improve intestinal anastomosis healing.
Beyond its GI applications, BPC-157 shows broad systemic benefits. It counteracts all phases of inflammation — acute, subacute, and chronic — while maintaining and restoring gut barrier integrity. It has shown protective effects against NSAID and paracetamol toxicity, counteracts the harmful effects of systemic corticosteroid therapy, and attenuates direct liver lesions, gastric lesions, and portal hypertension from acute and chronic alcohol exposure. In pancreatic and hepatic models, it counteracts effects of common bile duct ligation, hepatomegaly, and fatty liver.
BPC-157 also demonstrates therapeutic potential beyond the GI tract. In the musculoskeletal system, it supports healing of muscle, tendon, ligament, and bone injuries, including arthritis. Neurologically, it provides neuroprotective effects and shows promise for traumatic brain injury and nerve crush injuries. Cardiovascularly, it supports myocardial tissue repair and membrane stabilization, including counteracting digoxin toxicity.